Andere Sprachen PDS Biotechnology Corporation

Aktien

A2PF3F

US70465T1079

PDSB

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:08:35 01.05.2024			% 5 Tage	% 1. Jan.
3,595 ^USD	+7,31 %		+8,88 %	-28,80 %

28.03.	PDS BIOTECHNOLOGY CORPORATION : B. Riley behält die Bewertung Kaufen bei	ZM
27.03.	Empire Metals strebt wichtige Meilensteine in Australien an	AN

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer	24.04.
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer	23.04.
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	28.03.
Empire Metals targets key milestones in Australia	27.03.
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	27.03.
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
North American Morning Briefing : Stocks Edge -2-	27.03.
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results	20.03.
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®	13.03.
PDS Biotechnology : Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® - Form 8-K	13.03.
PDS Biotechnology Corporation Announces Publication of Preclinical Research	13.03.
PDS Biotechnology Names Kirk Shepard as Chief Medical Officer	22.01.
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer	22.01.
PDS Biotechnology Corporation Announces Executive Changes	22.01.
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference	16.01.
PDS Biotechnology Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	05.12.
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	04.12.
Apyx Medical Names Matthew Hill as CFO	28.11.
PDS Biotechnology Appoints Lars Boesgaard as Finance Chief	28.11.
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer	28.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PDS Biotechnology Corporation

Aktien

A2PF3F

US70465T1079

PDSB

Andere Sprachen

Filter